Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax Inc (NQ: NVAX )

9.120 -0.230 (-2.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax Inc

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
59 60 Next >
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Novavax Scores Another Nod For Its COVID-19 Shot In Adolescents
Via Benzinga
Novavax Obtains U.K. Regulatory Clearance For Nuvaxovid In Adolescents Aged 12-17 Years
The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has granted expanded conditional marketing authorization (CMA) for Novavax’s (NASDAQ: NVAX) lead asset... 
Via Benzinga
Pfizer And Moderna Are In A Race With Omicron; Will The Vaccine Stocks Be Too Late?
The companies hope to launch updated boosters this fall. This is what experts think of their prospects. 
Via Investor's Business Daily
Face Of US COVID-19 Response, Dr Anthony Fauci To Retire In December
  
Via Benzinga
FDA Approves Novavax's COVID-19 Vaccine For Use In Adolescents
Via Benzinga
Novavax Seeks FDA Emergency Use Nod For Its COVID-19 Vaccine Booster
Via Benzinga
Why Novavax Stock Is Plunging Today
Novavax Inc (NASDAQ: NVAX) shares are tanking Tuesday after the company reported financial results and slashed its full-year guidance. 
Via Benzinga
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
How they handle an upcoming shift in payments will be telling for their tailwind. 
Via Investor's Business Daily
Novavax's Covid-19 Vaccine Cleared For Use In New Zealanders Aged 12-17
Via Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Gainers 
Via Benzinga
If You Invested $1,000 In Johnson & Johnson Stock At Its COVID-19 Pandemic Low, Here's How Much You'd Have Now
Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than... 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022
Via Benzinga
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
  Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split. 
Via Benzinga
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus... 
Via Benzinga
Here's How Much You Would Have Made Owning Novavax Stock In The Last 5 Years
  Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 3.21% on an annualized basis producing an average annual return of 14.91%. Currently, Novavax has a market capitalization of... 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Here's Why Novavax Shares Are Trading Higher
Novavax, Inc. (NASDAQ: NVAX) shares are trading higher by 2.80% to $41.47, though off the session high of $43.06 after the company announced its Novaxovid COVID-19 vaccine has been approved in South... 
Via Benzinga
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
The major indexes continued to advance, despite some key warnings. 
Via Investor's Business Daily
Blue Water Vaccines: Early Stage Developer Of Infectious Disease Vaccines
Is BWV a buy? We sat down with Blue Water Vaccines management to find out what the company has been up to and what have in store for the future. 
Via Talk Markets
Peak Inflation: July CPI Report Was Much Better Than Expected
(Wednesday Market Open) The report everyone was waiting for this week finally came out with the Consumer Price Index (CPI) coming in lower-than-expected and prompting equity index futures to rally.  
Via Benzinga
Retail Investors Pile Into Meme Stocks Despite Violent Selloff
Retail investors are doubling down on shares of meme stocks including Bed Bath & Beyond and AMC Entertainment on Tuesday, even as the powerful meme stonk rally that showed shades of last year’s mania... 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Micron Technology, Novavax, CarGurus And Some Other Big Losers From Tuesday
U.S. stocks closed lower, with the Nasdaq dropping 150 points on Tuesday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
Why Is Novavax (NVAX) Stock Plunging 30%?
Shares of NVAX stock are falling after the company cut its revenue outlook in half and delivered a poor Q2 earnings report. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD.... 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.